Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4141650 | 1.00 | CA12 (0.32) | CA12CA1CA2MMP1MMP2 | |
| SCHEMBL17050367 | 1.00 | CA12 (0.32) | CA12CA1CA2MMP1MMP2 | |
| Oxalic Acid SCHEMBL11793800 | 0.89 | CA12 (0.35) | CA12CA1CA2MMP1MMP2 | |
| SCHEMBL15927997 | 0.80 | — | — | |
| SCHEMBL10548828 | 0.80 | — | — | |
| SCHEMBL9825498 | 0.80 | — | — | |
| SCHEMBL9432221 | 0.80 | — | — | |
| SCHEMBL613869 | 0.77 | CTSK (0.32) | CA1CA2 | |
| SCHEMBL94143 | 0.77 | CTSK (0.32) | CA1CA2 | |
| SCHEMBL94144 | 0.77 | CTSK (0.32) | CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025083736-A1 | NOVEL PROCESS FOR THE PREPARATION OF PIRTOBRUTINIB AND ITS INTERMEDIATES THEREOF | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2025-04-24 | — | — | WO | claimed |
| EP-3679013-B1 | METHOD FOR MAKING ISOCYANATES | COVESTRO INTELLECTUAL PROPERTY GMBH & CO KG (DE) | 2023-11-29 | — | — | EP | claimed |
| CN-111051276-B | Method for producing isocyanates | 科思创德国股份有限公司 | 2022-09-09 | — | — | CN | claimed |
| US-10858310-B1 | Method for producing isocyanates | COVERSTRO DEUTSCHLAND AG (DE) | 2020-12-08 | — | — | US | claimed |
| US-20200361856-A1 | METHOD FOR PRODUCING ISOCYANATES | COVESTRO DEUTSCHLAND AG (DE) | 2020-11-19 | — | — | US | claimed |
| WO-2007142700-A1 | COPPER (I) AMIDINATES AND GUANIDINATES FOR FORMING COPPER THIN FILMS | ADVANCED TECHNOLOGY MATERIALS, INC. (US) | 2007-12-13 | — | — | WO | claimed |
| EP-4692940-A1 | PHOTOSENSITIVE RESIN COMPOSITION, CURED FILM, ELECTRONIC DEVICE, AND ELECTRONIC DEVICE MANUFACTURING METHOD | Sumitomo Bakelite Co., Ltd. (JP) | 2026-02-11 | — | — | EP | disclosed |
| US-12421211-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| EP-4565574-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2025-06-11 | — | — | EP | disclosed |
| WO-2025083736-A1 | NOVEL PROCESS FOR THE PREPARATION OF PIRTOBRUTINIB AND ITS INTERMEDIATES THEREOF | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2025-04-24 | — | — | WO | disclosed |
| CN-119731159-A | SARS-CoV2 main proteinase inhibitor | 吉利德科学公司 | 2025-03-28 | — | — | CN | disclosed |
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2025-02-06 | — | — | US | disclosed |
| EP-0647133-A1 | COMPOSITIONS AND METHODS FOR ENHANCED DRUG DELIVERY | AFFYMAX TECHNOLOGIES N.V. (AN) | 1995-04-12 | — | — | EP | disclosed |
| WO-1993025197-A1 | COMPOSITIONS AND METHODS FOR ENHANCED DRUG DELIVERY | AFFYMAX TECHNOLOGIES N.V. (AN) | 1993-12-23 | — | — | WO | disclosed |
| US-5196478-A | Polystyrene, assays | EPIPHARM ALLERGIE-SERVICE GESELLSCHAFT M.B.H. (AT) | 1993-03-23 | — | — | US | disclosed |
| WO-1992020336-A2 | NOVEL CHOLESTEROL LOWERING COMPOUNDS | MERCK & CO., INC. (US) | 1992-11-26 | — | — | WO | disclosed |
| EP-0512865-A2 | Novel cholesterol lowering compounds | MERCK & CO. INC. (US) | 1992-11-11 | — | — | EP | disclosed |
| US-4431576-A | COSMETICS; TOILETRIES; DETERGENTS; INSECTICIDES; WAXES | ROUSSEL UCLAF (FR) | 1984-02-14 | — | — | US | disclosed |
| US-3947274-A | Silver halide photographic material containing an isourea derivative as antifoggant | FUJI PHOTO FILM CO., LTD. (JA) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | CA12 609/4885CA1 2925/4885CA2 426/4885 |
| US-12421211-B2 | Heterocyclic compounds | F12, C1R, MRPL21 | CA12 4230/4885CA1 4605/4885CA2 3966/4885 |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | ACE2, TMPRSS2, ACE | CA12 609/4885CA1 2925/4885CA2 426/4885 |
| US-20200361856-A1 | METHOD FOR PRODUCING ISOCYANATES | IDH2, ADH5, ADH1C | CA12 249/4885CA1 260/4885CA2 170/4885 |
| US-10858310-B1 | Method for producing isocyanates | IDH2, ADH5, ADH1C | CA12 249/4885CA1 260/4885CA2 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.